ReviewCurrent hematologic malignancy reports2014
Epidemiology of MPN: what do we know?
Review in Current hematologic malignancy reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Network pharmacology-based analysis of the antithrombotic clinical efficacy and antithrombotic mechanism of Huoxue Jiedu prescription in the treatment of polycythemia vera with heat toxin and blood stasis syndrome.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025Trial
- Ophthalmological and epidemiological profiles of Brazilian patients with philadelphia-negative Myeloproliferative neoplasms.Hematology, transfusion and cell therapy · 2026Article
- Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio as novel prognostic biomarkers in BCR-ABL negative myeloproliferative neoplasms.Annals of hematology · 2024Article
- Article
- Blood sampling patterns in primary care change several years before a cancer diagnosis.Acta oncologica (Stockholm, Sweden) · 2024Article
- Article
- Expression profiles analysis identifies specific interferon-stimulated signatures as potential diagnostic and predictive indicators ofFrontiers in genetics · 2022Article
- Review
- NK Cells in Myeloproliferative Neoplasms (MPN).Cancers · 2021Review
- Genetic polymorphisms associated with telomere length and risk of developing myeloproliferative neoplasms.Blood cancer journal · 2020Article
- Mathematical Modeling of MPNs Offers Understanding and Decision Support for Personalized Treatment.Cancers · 2020Article
- Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms.Cancers · 2020Review
- Incidence of myeloproliferative neoplasms - trends by subgroup and age in a population-based study in Sweden.Journal of internal medicine · 2020Article
- Polycythemia Vera.Current treatment options in oncology · 2018Review
- Molecular Pathogenesis of Myeloproliferative Neoplasms: Influence of Age and Gender.Current hematologic malignancy reports · 2017Review
- Myeloid malignancies in the real-world: Occurrence, progression and survival in the UK's population-based Haematological Malignancy Research Network 2004-15.Cancer epidemiology · 2016Article
- Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011.Journal of cancer research and clinical oncology · 2015Article
- A comprehensive review of pacritinib in myelofibrosis.Future oncology (London, England) · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The myeloproliferative neoplasms, are characterised by overproduction of myeloid cells. Chronic myeloid leukaemia, polycythaemia vera, essential thrombocythaemia, myelofibrosis and the very rare disorders chronic neutrophilic leukaemia, chronic eosinophilic leukaemia not otherwise specified and mastocytosis are all included in the group. Incidence and prevalence rates reported in the worldwide literature are presented in this review. Survival data on each condition is described. Information on the aetiology of the disorders is discussed including body mass index, diet, smoking and alcohol, allergies, associated medical conditions, occupation and environmental exposures with focus on recent new studies. The aetiology of the myeloproliferative neoplasms remains unknown, and this review of the current state of knowledge highlights the need for further comprehensive research.
Indexed as
Identifiers
25129052What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.